Chronic Inflammatory Demyelinating Polyneuropathy
44
12
16
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
4.5%
2 terminated out of 44 trials
86.7%
+0.2% vs benchmark
23%
10 trials in Phase 3/4
54%
7 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (44)
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
IVIG vs SCIG in CIDP
An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy
Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
NT-3 Levels and Function in Individuals With CMT
Vitaccess Real CIDP Registry